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Background. In urban Guinea-Bissau, adults with a vaccinia scar had better survival but also a higher prevalence of HIV-2
infection. We therefore investigated the association between vaccinia scar and survival and HIV infection in a rural area of
Guinea-Bissau. Methodology/Principal Findings. In connection with a study of HIV in rural Guinea-Bissau, we assessed
vaccinia and BCG scars in 193 HIV-1 or HIV-2 infected and 174 uninfected participants. Mortality was assessed after 2K–3 years
of follow-up. The analyses were adjusted for age, sex, village, and HIV status. The prevalence of vaccinia scar was associated
with age, village, and HIV-2 status but not with sex and schooling. Compared with individuals without any scar, individuals
with a vaccinia scar had better survival (mortality rate ratio (MR)=0.22 (95% CI 0.08–0.61)), the MR being 0.19 (95% CI 0.06–
0.57) for women and 0.40 (95% CI 0.04–3.74) for men. Estimates were similar for HIV-2 infected and HIV-1 and HIV-2 uninfected
individuals. The HIV-2 prevalence was higher among individuals with a vaccinia scar compared to individuals without a vaccinia
scar (RR=1.57 (95% CI 1.02–2.36)). Conclusion. The present study supports the hypothesis that vaccinia vaccination may have
a non-specific beneficial effect on adult survival.
Citation: Jensen ML, Dave S, van der Loeff MS, da Costa C, Vincent T, et al (2006) Vaccinia Scars Associated with Improved Survival among Adults in
Rural Guinea-Bissau. PLoS ONE 1(1): e101. doi:10.1371/journal.pone.0000101
INTRODUCTION
Vaccinia vaccination was introduced in 1800 and was associated
with marked reductions in mortality in the industrialising countries
[1]. The last case of smallpox occurred in 1977 [2] and in 1980 the
World Health Organization recommended stopping vaccinia
vaccinations. No assessment was made of the health impact of
discontinuing vaccination.
Vaccines may have non-targeted effects–that is, effects which
can not be explained by the prevention of the vaccine targeted
infection. Live vaccines, including measles and BCG vaccines [3–
7] have been associated with reductions in overall mortality which
cannot be explained merely by the prevention of measles or
tuberculosis infection. Studies have also consistently found that
such non-targeted effects are larger for females [3,7–9]. These
observations made us study the possible non-targeted effects of
vaccinia. A study of 1,893 adults from Guinea-Bissau conducted
between 1998 and 2002 showed lower mortality among vaccinia
scar positive individuals more than 20 years after the last vaccinia
vaccinations. Adults with a smallpox scar had a mortality rate ratio
(MR) of 0.60 (0.41–0.87) compared to those without any scar.
Also, individuals with a vaccinia scar had larger mid-upper-arm-
circumference (MUAC) than individuals without a scar and
a larger MUAC was associated with better survival [10].
Scientists from the MRC Laboratories, The Gambia, have
examined HIV-2 infection in rural Guinea-Bissau for the last
15 years [11–18]. Due to the surprising association between
vaccinia scars and survival in urban Bissau, the team was asked to
investigate the possible role of vaccinia vaccinations for survival in
rural Guinea-Bissau.
METHODS
An HIV-2 study has been conducted in Caio, a rural area in
Guinea-Bissau since 1989. Detailed descriptions are provided
elsewhere [11,12,15]. Briefly, two general population surveys were
conductedin1989–91and1997.Followingtheinitialsurvey,acase-
control study examining clinical conditions and immunological
parameters was conducted in 1991. Those enrolled in this study
were re-examined in 1996 and 2003. The 2003 study round
included additional HIV-1 and HIV-2 infected individuals
identified in the 1997 population study and a similar number of
new controls who were frequency-matched according to sex, age,
and village were included. The 2003 study included 402 individuals
of whom 145 were HIV-2 single infected, 29 were HIV-1 single
infected, 30 were dually infected, and 198 were HIV negative.
HIV-infected and uninfected individuals were invited for
a clinical examination conducted by a physician and blood
samples were collected for assessment of HIV and HTLV
infections as well as for T-cell subsets, malaria, anaemia, and
sexually transmitted infections. As part of the clinical examination,
the mid upper-arm circumference (MUAC) was measured in mm
using a TALC insertion tape (Teaching Aids at Low Cost, St.
Albans, England).
During the clinical examination, the physician examined the
presence of vaccinia and BCG vaccination scars on fore and upper
arms. Scar reading was conducted by 4 medical doctors of whom
one (SD) examined 78% of the participants. The physicians had
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questionnaire had room for noting three scars. If there were more
than three scars these would usually include several vaccinia scars
and a BCG scar. The physicians were told to register at least one
scar of each type, i.e. both vaccinia and BCG. The procedure may
have led to underreporting of people with more than two vaccinia
scars. The number of scars were therefore only analysed as 2 or
more scars versus one vaccinia scar. For each scar the height and
width were measured with a ruler. The average of the two
diameters was used as an overall index of the size of the scar. Also
the location of the scar was marked. Scars were classified as
vaccinia, BCG, or ‘‘unknown origin’’. Based on the experience
from Bissau, the protocol specified that vaccinia scars are usually
more than 10 mm, have a smooth central area and a rough
peripheral rim whereas BCG scars are usually small (,8 mm) and
smooth.
Survival was assessed in early 2006. Annual censuses have been
conducted between 2003 and 2006. In February 2006, field
assistants verified all identified deaths and visited all study
participants who had not been seen in a clinical examination
conducted in January and February 2006. A few additional deaths
were identified as a result of these visits; survival status could be
ascertained of all participants
The main ethnic group in Caio is the ‘‘Manjaco’’ which has
a traditional age group system; with intervals of around 4 years
a new age cohort is established. The group will have a unique
name and individuals will belong to this cohort for the rest of their
life. In a specific age group, the females are a few years younger
than the males. Individuals are socially attached to their group and
will remember the name of the group to which they belong. This
traditional age group system is likely to reflect relative age better
than official chronological age from the colonial era. The birth day
is poorly remembered and may be manipulated for reason of tax,
military service, or admission to school. Hence, the traditional
system is likely to be more accurate than the self-reported
chronological age. The majority of the people in the study area
were Manjacos but 9 individuals belonged to other groups and
were age classified according to the self-reported chronological
age. In all analyses, we adjusted for age using age sets consisting of
three sequential Manjaco age groups.
Statistical analysis
The study from urban Bissau revealed that few had received
vaccinia vaccination before school-age, the median age of
vaccination being 18 years [10]. Since vaccinia vaccinations were
stopped in Guinea-Bissau in 1980, we only included individuals
born before 1974 in the previous [10] and the present analysis. A
Cox proportional hazards model [19] was used to assess the
mortality ratio for vaccinated and unvaccinated individuals. The
Cox model had follow-up time as underlying time and followed
the individuals from the initial assessment of scars and until death
or the survey in 2006. Age was controlled using the traditional age
group system described above. HIV status was categorised as
HIV-1, HIV-2 only, and HIV negative. The association between
vaccination scar status and respectively HIV-2 seropositivity and
MUAC was analysed by using a general linear model. HIV-1 was
not present in Guinea-Bissau when smallpox vaccination was still
in use. Hence, we have not assessed the association between scar
and HIV-1 infection.
RESULTS
Of the 402 persons taking part in the study, 367 were born before
1974. Of these, 141 were only HIV-2 infected, 23 were only HIV-
1 infected, 29 were dually infected, and 174 were uninfected. The
distribution of these 367 individuals on the three types of scar
(vaccinia, BCG, unknown) is indicated in Table 1; 68% (N=251)
had a vaccinia scar (Table 1), and of these 58% (146/251) had
additionally a BCG or a scar of unknown origin. Of the 116
individuals without a vaccinia scar, 70% (81/116) had a BCG or
a scar of unknown origin. A total of 44% (160/367) of the cohort
had a BCG scar, and 34% (123/367) had a scar of unknown
origin. Ten percent (35/367) had no vaccination scar. The median
diameter was 20 mm (25–75 percentiles: 16–24 mm) for vaccinia
scars, 10 mm (6–15 mm) for BCG scars, and 8 mm (5–11 mm) for
scars of unknown origin. As seen in table 2, vaccinia vaccination is
strongly associated with age group. There was no significant
difference in the vaccinia scar prevalence for men and women, the
prevalence ratio being 1.11 (95% CI 0.97–1.27) controlled for age.
The prevalence of vaccinia scar was associated with village
(Table 2). No association was found between years of schooling
(Table 2) or current alcohol consumption pattern (data not shown)
and the presence of vaccinia scar.
The mean mid-upper-arm-circumference (MUAC) was
284 mm (range 152–390) for individuals with a vaccination scar
and 266 mm (182–352) for individuals without any scar (un-
adjusted, p=0.009), the difference being highly significant in an
analysis adjusting for sex, age and HIV status (p,0.001). The
differential effect was found only among women, the estimated
difference between vaccinia scar positive women and women
without any scar being 21.0 mm (6.4–35.6) unadjusted, and
21.7 mm (7.3–36.2) when adjusted for age-group and HIV status.
Over the three years of follow-up, 13% (47/367) of the
individuals in the cohort died (Table 3). Individuals with
a vaccinia-scar had lower mortality than individuals without any
scar, the crude mortality rate ratio (MR) being 0.41 (0.19–0.86).
Adjusting for age, sex, village and HIV status, the MR was 0.22
(95% CI 0.08–0.61)). The MR for women was 0.19 (95% CI 0.06–
0.57) and 0.40 (95% CI 0.04–3.74) for men. The tendency was the
same comparing individuals with any scar with individuals without
any scar, the MR being 0.25 (95% CI 0.10–0.62) (Table 3).
Estimates were beneficial for both HIV-2 infected (MR=0.19
(0.04–0.79)) and HIV-negative individuals (MR=0.20 (0.06–
0.71)), controlling for age, sex and village. Mortality was 16%
(18/116) for those without a vaccinia scar, 12% (25/203) for those
with one vaccinia scar and 8% (4/48) for those with 2 or 3 scars.
Individuals with 2 or more vaccinia scars may had a MR of 0.14
(0.03–0.56), and those with only one vaccinia scar a MR of 0.24
(0.09–0.68) compared with those without any scar.
As seen in Table 2, HIV-2 infected individuals were more likely
to have a vaccinia scar. In other words, the prevalence of HIV-2
infection was 52% (131/251) among people with a vaccinia scar
but only 34% (39/116) among those without. The prevalence ratio
(PR) of HIV-2 infection was 1.57 (95% CI 1.14–1.96) controlled
Table 1. Vaccinia, BCG and unknown scars among 367
residents born before 1974.
......................................................................
Scar status Vaccinia + No Vaccinia Total
BCG+ Unknown scar + 37 19 56 (15%)
No Unknown scar 77 27 104 (28%)
No BCG Unknown scar + 32 35 67 (18%)
No Unknown scar 105 35 140 (38%)
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compared to those without. The association appeared to be
stronger for men (PR=2.99 (1.25–7.15)) than for women
(PR=1.31 (0.94–1.84)). The prevalence ratio for individuals with
a vaccinia scar was 2.08 (95% CI 1.14–3.78) compared with
individuals without any scar. A presence of vaccinia scar was not
associated with HTLV infection.
DISCUSSION
The present study was initiated to investigate whether the
surprising observations of an association between vaccinia scar
and HIV-2 infection and of lower mortality among adults with
a vaccinia scar could be repeated. Data collection was independent
of data collection in the original study from urban Bissau [10]. The
major observations were clearly repeated. The presence of
a vaccinia scar was associated with lower mortality and more
HIV-2 infection. Additionally, as in Bissau, the beneficial effect of
vaccinia scar was strong for women. As found previously, vaccinia
scar positive individuals had larger MUACs than scar negative
individuals, but only among women. An association with better
survival was found for both HIV negative and HIV-2 infected
individuals.
Though vaccinia scars are generally larger than BCG scars,
there is no exact way to identify whether a scar is due to vaccinia
or BCG. The scar classification was made by a physician without
knowledge of the participant’s HIV-status. The difference in size
between vaccinia and BCG scars was similar in Caio and Bissau.
However, the measurement of scars in Caio was slightly larger
than in previous studies [10,20,21] and the prevalence of scars of
unknown origin was higher in Caio than in Bissau [10]. Some
misclassification is therefore likely and a reexamination of some
participants did suggest that some vaccinia scars had been
classified as BCG or ‘‘unknown’’. There was high agreement
about positive vaccinia scar readings. It is unlikely that the
classification of ‘‘no scar’’ has been differential according to
mortality. Hence, misclassification may have led to conservative
estimates. It is reassuring that all scars, including BCG and
unknown scars, were still strongly associated with better survival.
Hence, the main result is not due to a peculiar misclassification of
Table 3. Mortality according to sex, age, and scar status.
..................................................................................................................................................
Deaths/persons
Vaccinia scar versus no scar Any scar versus no scar



















1 (1967–1973) 0/1 1/7 0/9 0/4 0/1 2/17 0/9 1/10
2 (1955–1966) 0/1 7/23 0/3 1/31 0/1 9/31 0/3 1/46
3 (1943–1954) 5/27 1/1 4/57 6/31 1/1 6/66
4 (1931–1942) 4/16 0/7 6/60 4/18 0/7 6/72
5 (1919–1930) 1/2 0/3 3/5 1/20 1/2 0/5 3/5 1/28
6 (1907–1918) 0/1 4/6 0/2 K 4/6 1/6
All J 17/77 8/31 12/174 J 22/107 8/31 16/228
Crude MR 0.85 (0.38–1.91) 0.23 (0.10–0.56) 0.71 (0.10–5.27) 0.24 (0.10–0.57)
0.41 (0.19–0.86) 0.41 (0.19–0.86) 0.41 (0.20–0.84) 0.41 (0.20–0.84)
Adjusted MR 0.40 (0.04–3.74)* 0.19 (0.06–0.57)* 0.45 (0.05–3.74)* 0.22 (0.08–0.59)*
0.22 (0.08–0.61)** 0.22 (0.08–0.61)** 0.25 (0.10–0.62)** 0.25 (0.10–0.62)**
*Adjusted for traditional age set, village and HIV-status









































































Table 2. Prevalence of vaccinia scars by sex, age, village, years
of schooling, and HIV-2 status.
......................................................................
Age group (birth year) Males Females All
1 (1967–1973) 39% (7/18) 21% (4/19) 30% (11/37)
2 (1955–1966) 72% (23/32) 63% (31/49) 67% (54/81)
3 (1943–1954) 87% (27/31) 83% (57/67) 86% (84/98)
4 (1931–1942) 89% (16/18) 76% (60/79) 78% (76/97)
5 (1919–1930) 43% (3/7) 61% (20/33) 58% (23/40)
6 (1907–1918) 50% (1/2) 17% (2/12) 21% (3/14)
All 71% (77/108) 67% (174/259) 68% (251/367)
p-value 0.002 ,0.0001 ,0.0001
Village Males Females All
Centre I 79% (31/39) 78% (78/100) 78% (109/139)
Villages in-between 62% (23/37) 51% (44/86) 54% (67/123)
Centre II 72% (23/32) 70% (52/73) 73% (75/105)
p-value 0.25 0.0001 0.0001
Schooling (years) Males Females All
0 70% (21/30) 69% (146/211) 69% (167/241)
1–4 74% (34/46) 63% (20/32) 69% (54/78)
5–11 69% (22/32) 50% (8/16) 63% (30/48)
p-value 0.87 0.24 0.64
HIV-2 status Males Females All
HIV-2 infected 86% (44/51) 73% (87/119) 77% (131/170)
HIV-2 uninfected 58% (33/57) 62% (87/140) 61% (120/197)
p-value 0.001 0.061 0.001












































































































PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e101healthy individuals as having vaccinia scars rather than BCG or
unknown.
Better survival among vaccinia-vaccinated individuals could be
due to privileged groups being more likely to have received
vaccination. In Bissau, vaccination was associated with entering
secondary school, entering the military, international travels, and
getting a job in the public sector [10]. Hence, more men than
women were vaccinated according to the vaccination register of
Bissau. However, controlling for these factors in the analysis had
no impact on the estimated beneficial effect of vaccinia. In
a remote rural setting, these selection factors are likely to have had
much less impact as presumably most individuals were vaccinated
in the occasional campaigns; for example, sex and years of
schooling were not related to vaccinia scar prevalence in the study
area. The coverage was highest in the villages near the two largest
centres in which the campaigns were conducted in the colonial era
(Table 1). The villages in-between might have had a lower
coverage. Age was also associated with vaccination in the present
study. Vaccinia coverage was lower among the youngest and the
oldest, presumably certain age group were more likely to be called
for vaccination in the campaigns. There may have been other
determinants of vaccinia vaccination that we have no information
about. For example, people sick or travelling on the day of
vaccination campaign are unlikely to have received vaccinia
subsequently. However, it seems unlikely that such factors would
still play a role as confounding factors for survival 30–70 years
later. Control for age, sex, and village did not modify the estimated
beneficial effect of vaccinia vaccination.
The HIV-2 virus is endemic only in West-Africa. Few studies
have examined the initial propagation of the HIV-2 virus in West-
Africa. The epidemiology of HIV-2 is consistent with a period of
more intense transmission in the 1950s or 1960s. A study from
Guinea-Bissau suggested that the war of independence in 1963–74
may have been critical for the initial spread presumably due to the
commercial sex and access to blood transfusions associated with
the war [22]. The present and the previous study from Bissau city
[10] suggest that smallpox vaccination campaigns in the same
period may have been important as well, presumably due to
insufficient sterilization of the knife or needle used for vaccination.
Vaccinia vaccinations had the same beneficial effects among HIV-
2 infected and HIV uninfected individuals.
Additional studies will have to be undertaken in other areas
where selection biases may have been less or different or where
original vaccination records are still available [23]. However, the
larger arm-circumference among vaccinia-vaccinated adults may
suggest that a biological process is involved. Furthermore, several
case control and cohort studies from high-income countries have
indicated that vaccinia vaccination may have had a protective
effect against such diverse diseases as malignant melanoma
[24,25], rhabdomyosarcoma [26], Crohn’s disease [27], asthma
[23], and multiple sclerosis [28]. One study found better survival
among malignant melanoma patients who had a vaccinia
vaccination [29].
Our studies of vaccinia in Guinea-Bissau [10] and Denmark
[22] were initiated prior to the recent interest in smallpox infection
produced by bio-terrorism. Several previous studies had docu-
mented non-specific beneficial effects of live vaccines [3,4,6] and it
was therefore logical to examine whether vaccinia had similar
effects. So far the studies have supported that vaccinia may also
have non-specific beneficial effects. If confirmed, it raises questions
with major public health implications for low-income countries.
Vaccinia induces long-term cellular immunity [30–32]. In animal
models poxvirae may induce heterologous immunity, i.e. cross
protection against other infections [33,34]. Hence, it would seem
important in humans to examine possible cross reactions between
vaccinia responses and other infections as we might gain insight
into the long term non-specific beneficial effects of this and other
live vaccines. Vaccinia is very potent and now is regarded as
having an unacceptably high incidence of side-effects, hence the
use of modified vaccinia Ankara (MVA) as a vaccine and as
a vector for other antigens [32]. It would seem important to
examine whether MVA might have non-specific beneficial effects
as well.
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